Related Experiment Video

Updated: May 16, 2026

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral

Aaron I Vinik1, Anthony H Cincotta, Richard E Scranton

  • 1Strelitz Diabetes Center and Neuroendocrine Unit, Norfolk, Virginia, USA.

Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
|November 29, 2012
PubMed
Abstract

Insights

Bromocriptine-QR significantly improved glycemic control in type 2 diabetes patients inadequately managed with oral agents. This study found bromocriptine-QR added to existing therapies led to better HbA1c levels compared to placebo.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Type 2 diabetes mellitus (T2DM) affects millions globally, often requiring complex management strategies.
  • Poor glycemic control in T2DM is linked to severe long-term complications.
  • Oral anti-diabetes agents (OADs) are foundational, but many patients need additional therapies.

Purpose of the Study:

  • To evaluate the efficacy of bromocriptine-QR as an add-on therapy for T2DM.
  • To assess its impact on glycemic control in patients with suboptimal response to OADs.
  • To compare bromocriptine-QR versus placebo in improving HbA1c levels.

Main Methods:

  • A 24-week, randomized, double-blind, placebo-controlled trial.
  • 515 T2DM patients with HbA1c ≥ 7.5% on 1-2 OADs were randomized (2:1) to bromocriptine-QR or placebo.
  • Glycemic control was assessed by HbA1c changes and the odds of achieving HbA1c ≤ 7.0%.

Main Results:

  • Bromocriptine-QR treatment resulted in significantly greater HbA1c reductions compared to placebo across all analyzed subgroups.
  • Patients on bromocriptine-QR had a 1.5 to 2-fold higher likelihood of achieving target HbA1c levels (≤ 7.0%).
  • Fewer patients in the bromocriptine-QR arm required intensification of concomitant anti-diabetes medication.

Conclusions:

  • Bromocriptine-QR offers a significant therapeutic benefit for T2DM patients with poor glycemic control on OADs.
  • It provides added glycemic improvement beyond existing oral therapies.
  • This suggests bromocriptine-QR is a valuable option for enhancing diabetes management.

More Related Videos

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...